GLP-1 Medications: More Than Weight Loss—How They're Transforming Metabolic Medicine
- Aug 3
- 5 min read
By Staci Willis, FNP-C | Basix Health & Wellness
When most people hear about GLP-1 medications like Wegovy® (semaglutide), Ozempic® (semaglutide), or Zepbound® (tirzepatide), they think of one thing: weight loss.
While these medications have transformed obesity treatment, the latest research tells a much bigger story. GLP-1 receptor agonists—and the dual GIP/GLP-1 agonist tirzepatide—are improving health outcomes far beyond the number on the scale. In appropriately selected patients, these medications reduce cardiovascular events, improve heart failure symptoms, slow kidney disease progression, and now even treat obstructive sleep apnea.
This represents a fundamental shift in medicine. Rather than simply treating excess weight, we are increasingly treating metabolic disease and reducing the complications associated with it.
Understanding Metabolic Health
Obesity is not simply an issue of willpower or calorie balance. It is a chronic, complex disease involving hormonal regulation, inflammation, insulin resistance, appetite signaling, and energy metabolism.
Many people with obesity also develop:
Insulin resistance
Prediabetes or type 2 diabetes
High blood pressure
Abnormal cholesterol and triglycerides
Fatty liver disease (MASLD)
Obstructive sleep apnea
Heart disease
Chronic kidney disease
GLP-1 medications work by addressing many of these underlying metabolic disturbances. They help regulate appetite, improve insulin sensitivity, slow gastric emptying, reduce caloric intake, decrease visceral fat, and improve numerous cardiovascular and metabolic risk factors.
For many patients, the weight loss is simply one visible sign of much broader metabolic improvement.
Four Landmark Studies That Changed How We View GLP-1 Therapy
1. The SELECT Trial (2023)
Published in the New England Journal of Medicine, the SELECT trial enrolled more than 17,600 adults with overweight or obesity and established cardiovascular disease—but notably without diabetes.
Participants receiving semaglutide experienced:
20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death)
Significant weight loss
Improved overall cardiometabolic health
This was the first large study demonstrating that treating obesity can significantly reduce cardiovascular events in high-risk individuals.
Perhaps even more importantly, SELECT established obesity treatment as cardiovascular disease prevention.
2. The STEP-HFpEF Trial (2023)
Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as an obesity-related condition characterized by chronic inflammation and reduced exercise capacity.
Adults treated with semaglutide experienced:
Improved heart failure symptoms
Better quality of life
Increased exercise tolerance
Approximately 43% reduction in C-reactive protein (CRP), a marker of systemic inflammation
Fewer serious adverse events than those receiving placebo
These findings demonstrated that improving metabolic health can translate into meaningful improvements in cardiac function and day-to-day living.
3. The FLOW Trial (2024)
The FLOW trial evaluated adults with type 2 diabetes and chronic kidney disease.
Patients receiving semaglutide demonstrated:
24% reduction in kidney disease progression
18% reduction in cardiovascular events
Approximately 20% reduction in all-cause mortality
The benefits were so compelling that the study was stopped early because continuing the placebo group was no longer considered ethically appropriate.
This trial established GLP-1 therapy as an important treatment option for protecting kidney function while simultaneously reducing cardiovascular risk.
One of the newest milestones in obesity medicine came in December 2024, when the FDA approved tirzepatide (Zepbound®) as the first medication specifically indicated for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, alongside diet and physical activity.
Obstructive sleep apnea is much more than snoring. Repeated episodes of airway collapse during sleep reduce oxygen levels and increase the risk of hypertension, atrial fibrillation, heart attack, stroke, insulin resistance, and reduced quality of life.
In the SURMOUNT-OSA clinical trials, participants receiving tirzepatide experienced:
Significant reductions in the apnea-hypopnea index (AHI), meaning fewer breathing interruptions during sleep
Greater rates of remission or improvement to mild sleep apnea
Significant weight loss
Improvements whether patients were using CPAP or were unable or unwilling to use CPAP
This landmark approval further reinforces that treating obesity can improve multiple obesity-related diseases—not simply body weight.
CPAP remains an essential treatment for many individuals, but addressing the underlying metabolic disease provides another powerful tool for improving long-term health.
Who Benefits Most?
Current evidence strongly supports GLP-1 therapy for many patients with:
Obesity
Type 2 diabetes
Established cardiovascular disease
Chronic kidney disease associated with diabetes
Heart failure with preserved ejection fraction (HFpEF)
Moderate-to-severe obstructive sleep apnea with obesity
For these populations, GLP-1 therapy has demonstrated improvements in meaningful clinical outcomes—not simply weight loss.
Is BMI the Whole Story?
Not necessarily.
BMI is a useful screening tool, but it does not tell us everything about metabolic health.
In clinical practice, we also consider:
Waist circumference
Visceral fat
Fasting insulin
Hemoglobin A1c
Triglycerides and HDL cholesterol
Blood pressure
Liver health
Muscle mass
Family history
Overall cardiovascular risk
Two people with the same BMI can have dramatically different metabolic health.
For example, a patient with a BMI of 27 who has significant insulin resistance, fatty liver disease, elevated triglycerides, and central obesity may have considerably greater metabolic risk than someone with a BMI of 31 who is physically active with excellent metabolic markers.
Personalized medicine means treating the individual—not just the BMI.
What About Microdosing?
One topic receiving increasing attention is microdosing GLP-1 medications.
Some clinicians use lower-than-standard doses in carefully selected patients to help with:
Appetite regulation
Insulin resistance
Prediabetes
Polycystic ovary syndrome (PCOS), now also know as Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Prevention of weight regain
Medication tolerance
There is a biologically plausible rationale for this approach, and many clinicians report favorable real-world experiences.
However, it is important to distinguish between clinical experience and high-level evidence.
At present, there are no large randomized clinical trials demonstrating that microdosed GLP-1 therapy reduces cardiovascular events, extends lifespan, or provides the same long-term outcome benefits seen in SELECT, FLOW, STEP-HFpEF, or SURMOUNT-OSA.
That does not mean microdosing is ineffective. It simply means the scientific evidence has not yet caught up to what some clinicians are observing in practice. As research continues, we may better define which patients benefit most from lower-dose therapy.
Medication Is Only One Piece of the Puzzle
One topic that deserves more attention is muscle preservation.
Rapid weight loss without adequate protein intake and resistance training can result in loss of lean body mass along with fat.
At Basix Health & Wellness, preserving muscle is a key priority.
That means emphasizing:
Adequate daily protein intake
Progressive resistance training
Regular physical activity
Quality sleep
Stress management
Sustainable nutrition
The healthiest goal isn't simply losing weight—it's losing excess body fat while maintaining or building lean muscle, which supports strength, mobility, metabolic health, and healthy aging.
The Bottom Line
GLP-1 medications represent one of the most important advances in metabolic medicine in decades.
High-quality clinical evidence now supports their use in appropriately selected patients to reduce cardiovascular events, improve heart failure symptoms, slow diabetic kidney disease progression, and treat obesity-related obstructive sleep apnea.
These medications are not a shortcut to health, nor are they currently supported as a universal longevity therapy for healthy individuals. Instead, they are powerful tools that, when prescribed thoughtfully and combined with healthy lifestyle habits, can dramatically improve health and quality of life.
At Basix Health & Wellness, we believe in treating the root causes of metabolic disease through individualized care. Medication is one tool—but lasting success comes from combining evidence-based therapies with proper nutrition, strength training, muscle preservation, quality sleep, and sustainable lifestyle changes.
Our goal isn't simply helping you weigh less.
It's helping you live longer, healthier, and stronger.
References
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563.
Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023;389:1069-1084. doi:10.1056/NEJMoa2306963.
Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW Trial). New England Journal of Medicine. 2024;390:1885-1898. doi:10.1056/NEJMoa2403347.
Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine. 2024;391:1195-1207. doi:10.1056/NEJMoa2404881.
U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024.
American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. 2026.
American Association of Clinical Endocrinology (AACE). Clinical Practice Guideline for Comprehensive Medical Care of Patients with Obesity.
Obesity Medicine Association. Obesity Algorithm® (most current edition).
Comments